The Effect of Propofol Infusion on Total Antioxidant Status During Tourniquet-Induced Ischemia-Reperfusion Injury
Information source: Diskapi Teaching and Research Hospital
ClinicalTrials.gov processed this data on August 20, 2015 Link to the current ClinicalTrials.gov record.
Condition(s) targeted: Total Knee Arthroplasty; Tourniquet-Induced Ischemia-Reperfusion Injury
Intervention: Propofol (Drug); Placebo (Drug)
Phase: Phase 4
Status: Recruiting
Sponsored by: Diskapi Teaching and Research Hospital Official(s) and/or principal investigator(s): Derya Özkan, MD, Principal Investigator, Affiliation: Ministry of health Diskapi Yıldirim Beyazit Training and Research Hospital Anesthesiology Clinic Taylan Akkaya, MD, Study Chair, Affiliation: Ministry of health Diskapi Yıldirim Beyazit Training and Research Hospital Anesthesiology Clinic Ali Yalcindag, MD, Study Chair, Affiliation: Ministry of health Diskapi Yıldirim Beyazit Training and Research Hospital Biochemistry Clinic Tuba Hanci, MD, Study Chair, Affiliation: Ministry of health Diskapi Yıldirim Beyazit Training and Research Hospital Biochemistry Clinic Haluk Gümüs, MD, Study Chair, Affiliation: Ministry of health Diskapi Yıldirim Beyazit Training and Research Hospital Anesthesiology Clinic Namik Delibas, MD, Study Chair, Affiliation: Ministry of health Diskapi Yıldirim Beyazit Training and Research Hospital Biochemistry Clinic
Overall contact: Derya Özkan, MD, Phone: +903125962553, Email: derya_z@yahoo.com
Summary
The release of tourniquet produces reactive oxygen species which can cause injury. Propofol
is chemically similar to phenol-based free radical scavengers.
Plasma total antioxidant capacity is a well-established marker of the overall protective
effect of antioxidants in body fluids. The aim of the study is to investigate the effects of
propofol on ischemia-reperfusion injury in total knee arthroplasty (TKA).
Clinical Details
Official title: The Effect of Propofol Infusion on Total Antioxidant Status During Tourniquet-Induced Ischemia-Reperfusion Injury in Total Knee Arthroplasty
Study design: Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Investigator, Outcomes Assessor), Primary Purpose: Prevention
Primary outcome: The perioperative alternation of the venous blood total antioxidant capacity levels of the arms
Eligibility
Minimum age: 18 Years.
Maximum age: 65 Years.
Gender(s): Both.
Criteria:
Inclusion Criteria:
- ASA I-II physical status
- Unilateral total knee arthroplasty
- Age 18 years to 65 years
Exclusion Criteria:
- Severe central nervous system disorders
- Severe cardiopulmonary,renal,metabolic, or hepatic disease,
- Blood volume deficits,
- Coagulopathy,
- Allergy to local anesthetics,
- Peripheral neuropathies,
- Body mass index > 35,
- History of antioxidant drug use
Locations and Contacts
Derya Özkan, MD, Phone: +903125962553, Email: derya_z@yahoo.com
Ministry of health Diskapi Yıldirim Beyazit Training and Research Hospital Anesthesiology and Biochemistry Clinics, Ankara 06110, Turkey; Recruiting Derya Özkan, MD, Phone: +903125962553, Email: derya_z@yahoo.com
Additional Information
Starting date: June 2012
Last updated: July 11, 2012
|